Quest Diagnostics Receives Upgrade to 'Buy' by StockNews.com Analysts

Quest Diagnostics DGX Upgraded to 'Buy' Status

Investment researchers at StockNews.com have reevaluated their stance on Quest Diagnostics DGX, enhancing the clinical laboratory giant's rating from 'hold' to 'buy'. This adjustment was distributed to their investor clients on Wednesday, marking a positive shift in the company's stock market projection. Quest Diagnostics, a Fortune 500 entity, is recognized for its significant role in the healthcare industry, performing diagnostic tests in the United States, Puerto Rico, Mexico, and Brazil, as well as maintaining collaborative agreements with hospitals and clinics worldwide.

Broad Analyst Interest in Quest Diagnostics

Additionally, Quest Diagnostics has caught the eye of several other equity analysts who have recently shared their insights and reports about the company's performance and potential. These opinions further underscore the interest and confidence various market observers have in the DGX stock.

Peer Companies in Focus

While Quest Diagnostics enjoys its newly acquired 'buy' status, it is part of a broader industry landscape that includes companies such as Information Services Group, Inc. III, a technology research and advisory firm based in Stamford, Connecticut, and SEI Investments Company SEIC, a significant asset management portfolio corporation headquartered in Oaks, Pennsylvania. Another peer worth mentioning is the industrials company, though not necessarily a direct competitor, is Aiventis Inc. AIVAF, with its distinct market focus.

upgrade, buy, hold